Yu ML - Search Results

1

HCV Microelimination for High-risk Special Populations.

Huang CF, Chen GJ, Hung CC, Yu ML. Huang CF, et al. Among authors: yu ml. J Infect Dis. 2023 Sep 13;228(Suppl 3):S168-S179. doi: 10.1093/infdis/jiac446. J Infect Dis. 2023. PMID: 37703340 Review.

2

Long-term effects of interferon-based therapy for chronic hepatitis C.

Yu ML, Huang CF, Dai CY, Huang JF, Chuang WL. Yu ML, et al. Oncology. 2007;72 Suppl 1:16-23. doi: 10.1159/000111703. Epub 2007 Dec 13. Oncology. 2007. PMID: 18087178 Review.

3

Changing prevalence of hepatitis C virus infection among teenagers in an endemic area in Taiwan.

Huang CF, Huang JF, Dai CY, Yu ML, Lu SN, Hsieh MY, Lee LP, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL. Huang CF, et al. Among authors: yu ml. Trans R Soc Trop Med Hyg. 2008 Sep;102(9):929-34. doi: 10.1016/j.trstmh.2008.05.018. Epub 2008 Jul 7. Trans R Soc Trop Med Hyg. 2008. PMID: 18603274

4

Serum retinol-binding protein 4 is inversely correlated with disease severity of chronic hepatitis C.

Huang JF, Dai CY, Yu ML, Shin SJ, Hsieh MY, Huang CF, Lee LP, Lin KD, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL. Huang JF, et al. Among authors: yu ml. J Hepatol. 2009 Mar;50(3):471-8. doi: 10.1016/j.jhep.2008.10.023. Epub 2008 Dec 25. J Hepatol. 2009. PMID: 19155083

5

A crossing in therapy for hepatitis C virus genotype 2 or 3: increasing ribavirin dose with shortened duration or reducing ribavirin dose with standard duration.

Huang CF, Dai CY, Huang JF, Chuang WL, Yu ML. Huang CF, et al. Among authors: yu ml. Hepatology. 2009 Apr;49(4):1395-6; author reply 1396. doi: 10.1002/hep.22863. Hepatology. 2009. PMID: 19330867 No abstract available.

6

HBV infection in indigenous children, 20 years after immunization in Taiwan: a community-based study.

Huang CF, Dai CY, Chuang WL, Ho CK, Wu TC, Hou NJ, Wang CL, Hsieh MY, Huang JF, Lin ZY, Chen SC, Hsieh MY, Wang LY, Tsai JF, Chang WY, Yu ML. Huang CF, et al. Among authors: yu ml. Prev Med. 2009 Apr;48(4):397-400. doi: 10.1016/j.ypmed.2009.02.002. Epub 2009 Feb 12. Prev Med. 2009. PMID: 19463479

7

Hepatitis C virus infection and metabolic syndrome---a community-based study in an endemic area of Taiwan.

Huang JF, Chuang WL, Yu ML, Yu SH, Huang CF, Huang CI, Yeh ML, Hsieh MH, Yang JF, Lin ZY, Chen SC, Dai CY, Chang WY. Huang JF, et al. Among authors: yu sh, yu ml. Kaohsiung J Med Sci. 2009 Jun;25(6):299-305. doi: 10.1016/S1607-551X(09)70520-0. Kaohsiung J Med Sci. 2009. PMID: 19560994 Free article.

8

The substantial role of initial ribavirin dose on the response to peginterferon alpha/ribavirin therapy in patients with genotype 1b chronic hepatitis C.

Dai CY, Huang CF, Chuang WL, Huang JF, Yu ML. Dai CY, et al. Among authors: yu ml. Am J Gastroenterol. 2009 Sep;104(9):2358-9. doi: 10.1038/ajg.2009.246. Am J Gastroenterol. 2009. PMID: 19727098 No abstract available.

9

Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C.

Huang CF, Yang JF, Dai CY, Huang JF, Hou NJ, Hsieh MY, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL, Yu ML. Huang CF, et al. Among authors: yu ml. J Infect Dis. 2010 Mar;201(5):751-9. doi: 10.1086/650470. J Infect Dis. 2010. PMID: 20102281

10

Hepatitis C virus genotype 2/3 patients who can receive an abbreviated course of peginterferon/ribavirin: the important role of initial ribavirin doses.

Dai CY, Huang CF, Huang JF, Chuang WL, Yu ML. Dai CY, et al. Among authors: yu ml. Hepatology. 2010 May;51(5):1861-2; author reply 1862-4. doi: 10.1002/hep.23620. Hepatology. 2010. PMID: 20432270 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

793 results

Search Page

Filters